Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT06397911Phase 2Recruiting
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of FB825 in atopic dermatitis (AD), sponsored by Oneness Biotech Co., Ltd.. Started Aug 2024; status: recruiting.
02
Drugs
FB825
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06397911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397911.